© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
April 14, 2021
The PSMA-targeted radiopharmaceutical 177Lu-PSMA-617 is poised to become one of the first PSMA theranostics approved by the FDA.
April 02, 2021
Tagawa draws specific attention to the targeted radioligand therapy 177Lu-PSMA-617.
March 23, 2021
The targeted radioligand therapy 177Lu-PSMA-617 also improved progression-free survival when added to best standard of care (BSC) compared with BSC alone.
March 16, 2021
At the New York GU 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Phillip J. Koo, MD, highlighted the potential of next-generation imaging to revolutionize the management of patients with prostate cancer.
March 15, 2021
PSA response rate was higher with the investigational radioligand therapy.
March 02, 2021
The FDA is currently reviewing the results of these trials and is scheduled to make an approval decision by May 28, 2021.
February 13, 2021
The FDA is scheduled to make a decision on a new drug application for 18F-DCFPyL on or before May 28, 2021.
February 12, 2021
The novel PSMA-targeted radiopharmaceutical for PET identified M1 disease in the majority of patients examined who otherwise had locoregional disease, according to a subanalysis of the OSPREY trial.
January 25, 2021
Twelve percent of patients with negative results on conventional imaging had lesion localization on 18F-fluciclovine PET.
December 09, 2020
Dr. Declan G. Murphy discusses results from the phase 3 proPSMA study of Ga 68 PSMA-11 in patients with high-risk prostate cancer.